Premium
Front Cover: Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies (ChemMedChem 21/2018)
Author(s) -
Möller Carsten,
Bone Wilhelm,
Cleve Arwed,
Klar Ulrich,
Rotgeri Andrea,
Rottmann Antje,
SchultzeMosgau MarcusHillert,
Wagenfeld Andrea,
Schwede Wolfgang
Publication year - 2018
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201800681
Subject(s) - progesterone receptor , infertility , ulipristal acetate , endometriosis , receptor , medicine , pharmacology , endometrium , front cover , cover (algebra) , chemistry , gynecology , biology , pregnancy , estrogen receptor , engineering , cancer , family planning , mechanical engineering , population , environmental health , breast cancer , research methodology , genetics
The Front Cover shows vilaprisan, a highly selective progesterone receptor modulator (SPRM), bound to the progesterone receptor (PR). Gynecologic diseases such as uterine fibroids and endometriosis depend on progesterone receptor function. Women affected by these diseases may suffer from heavy menstrual bleeding, pelvic pain, and/or infertility. Based on its high potency, high selectivity for the PR, and favorable pharmacokinetic properties, vilaprisan has the potential to offer a medical solution addressing the high unmet need in these indications. More information can be found in the Full Paper by Wolfgang Schwede et al. on page 2271 in Issue 21, 2018 (DOI: 10.1002/cmdc.201800487).